![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | A61P 35/00 | (2006.01) |
C07K 16/30 | (2006.01) | ||
A61K 47/68 | (2017.01) |
(11) | Number of the document | 3773910 |
(13) | Kind of document | T |
(96) | European patent application number | 19717173.9 |
Date of filing the European patent application | 2019-03-29 | |
(97) | Date of publication of the European application | 2021-02-17 |
(45) | Date of publication and mention of the grant of the patent | 2024-07-24 |
(46) | Date of publication of the claims translation | 2024-09-25 |
(86) | Number | PCT/US2019/025057 |
Date | 2019-03-29 |
(87) | Number | WO 2019/191728 |
Date | 2019-10-03 |
(30) | Number | Date | Country code |
201862650277 P | 2018-03-29 | US |
(72) |
BHOWMIK, Shivarupam , US
WANG, Jianing , US
XIA, Jinming , US
BRADY, William , US
TIAN, Feng , US
|
(73) |
Ambrx, Inc. ,
10975 North Torrey Pines Road, La Jolla, CA 92037,
US
|
(74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | Humanizuoto antikūno prieš prostatai specifinį membraninį antigeną (PSMA) konjugatai su vaistu |
HUMANIZED ANTI-PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES |
Payment date | Validity (years) | Amount | |
2025-02-27 | 7 | 162.00 EUR |
2026-03-29 |